Activity Overview
Castleman disease (CD), a group of rare lymphoproliferative disorders that can be difficult to recognize and classify, has symptoms that overlap with those of lymphoma, autoimmune diseases, and infections. As a result, diagnostic delays are common, and optimal treatment selection remains uncertain, particularly for multicentric forms of the disease.
This Cases and Conversations virtual webcast uses interactive patient cases and expert discussion to address key challenges in the diagnosis and management of CD. Faculty will review current evidence and guideline-based approaches for unicentric CD, human herpesvirus 8 (HHV-8)-associated multicentric CD, and idiopathic multicentric CD (iMCD), to improve clinician confidence and patient care.
This educational activity is an archive of the live virtual symposium held on July 28, 2026.
System requirements for this online activity are available here.
The activity is free to all users.
Target Audience
This educational activity is directed toward physicians, hematologists, pathologists, dermatologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of hematological disorders.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize the clinical, laboratory, and pathologic features that should prompt consideration of CD
- Differentiate unicentric CD from multicentric subtypes, including HHV-8–associated and iMCD, using appropriate diagnostic testing and clinical context
- Apply evidence-based and guideline-recommended treatment strategies for CD based on subtype, severity, and response to initial therapy
Matthew Lunning, DO, FACP
Professor and James O. Armitage, MD, Chair of Hematologic Malignancies
Chief of Hematology
Medical Director, Gene and Cellular Therapy
Assistant Vice Chancellor for Clinical Research
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, ADC Therapeutics, AstraZeneca, BeOne, Bristol Myers Squibb, Fate Therapeutics, Genentech, Genmab, Incyte, Johnson & Johnson, Kite, Lilly, Lyell, Pfizer, Recordati SpA, Secura Bio, Veeva
Sudipto Mukherjee, MD, PhD, MPH
Clinical Assistant Professor, Department of Medicine
Member, Immune Oncology Program, Case Comprehensive Cancer Center
Case Western Reserve University
Physician, Department of Hematology and Medical Oncology
Cleveland Clinic Cancer Center
Cleveland, OH
Disclosures: Advisor, Consultant, Fee for Service Recipient: Aplastic Anemia and MDS International Foundation, BioPharm, Blueprint Medicines, Bristol Myers Squibb, CCM Biosciences, Celgene, Celgene/Acceleron, EUSA Pharma/Recordati, EUSA Pharma/Recordati Rare Diseases, Genentech and AbbVie, McGraw Hill, Novartis, Partnership for Health Analytic Research, Sobi; Grant/Research Funding: American Cancer Society (ACS), American Society of Hematology (ASH), Bristol Myers Squibb, Jazz, Novartis, VeloSano (Cleveland Clinic Foundation)
Frits van Rhee, MD, PhD, MRCP (UK), FRCPath
Professor of Medicine
Clinical Director, Myeloma Center
Associate Director, Clinical Science
Winthrop P. Rockefeller Cancer Institute
Charles and Clydene Scharlau Chair for Hematologic Malignancies
University of Arkansas for Medical Sciences
Little Rock, AR
Disclosures: Advisor, Consultant, Fee for Service Recipient: Bristol Myers Squibb, Castleman Disease Collaborative Network, GSK, Janssen, Pfizer, Recordati, Regeneron, Sanofi
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians Education Resource®, LLC is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This Application-based activity is approved for a maximum of 1.0 contact hour (1.0 CEU) under UAN # 0661-0000-26-022-H01-P.
Eligibility for credits requires full engagement with the enduring activity, completion of the post-activity assessment questions, completion and submission of the activity evaluation, NABP e-pid # and month/date of birth within 30 days of activity completion. No partial credits are given.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Recordati Rare Diseases Inc.